Incyte Corp traded at $120.97 this Friday November 13th, decreasing $0.73 or 0.60 percent since the previous trading session. Looking back, over the last four weeks, Incyte lost 8.43 percent. Over the last 12 months, its price rose by 16.15 percent. Looking ahead, we forecast Incyte Corp to be priced at 117.09 by the end of this quarter and at 109.73 in one year, according to Trading Economics global macro models projections and analysts expectations.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.